S. Stoev

发表

Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.

J. Javitch, J. Pin, I. Brabet, 2010, Nature chemical biology.

[The use of alkaline protease from Bacillus subtilis, strain DY, for the hydrolysis of amino acid and peptide esters (author's transl)].

S. Stoev, E. Golovinsky, B. Aleksiev, 1981, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Synthesis and Characterization of Fluorescent Antagonists and Agonists for Human Oxytocin and Vasopressin V1a Receptors

S. Stoev, M. Manning, B. Mouillac, 2002 .

Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

V. Boulay, G. Guillon, S. Stoev, 2011, Journal of medicinal chemistry.

Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.

S. Stoev, M. Manning, C. Barberis, 1995, Advances in experimental medicine and biology.

Design of Oxytocin Antagonists, which are more Selective than Atosiban

S. Stoev, M. Manning, W. Y. Chan, 2001, Journal of peptide science : an official publication of the European Peptide Society.

Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays

S. Stoev, M. Manning, W. Y. Chan, 2000, Experimental physiology.

Receptor‐Specific Antagonists of Vasopressin and Oxytocin

S. Stoev, M. Manning, W. H. Sawyer, 1993 .

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

G. Guillon, S. Stoev, M. Manning, 2007, Journal of medicinal chemistry.

Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

Mohamed Slim Ben Mimoun, G. Guillon, S. Stoev, 2004, Journal of medicinal chemistry.

[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.

G. Guillon, S. Stoev, M. Manning, 2002, Endocrinology.

Synthesis and properties of [A19-(p-fluorophenylalanine)] insulin.

S. Stoev, A. Wollmer, E. Golovinsky, 1988, Biological chemistry Hoppe-Seyler.

Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors

S. Stoev, M. Manning, W. Y. Chan, 1998, British journal of pharmacology.

Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

S. Stoev, M. Manning, A. Misicka, 1992, Journal of medicinal chemistry.

Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies.

S. Stoev, M. Manning, R. Levi, 2001, European journal of pharmacology.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

G. Guillon, S. Stoev, M. Manning, 2008, Progress in brain research.

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

G. Guillon, S. Stoev, M. Manning, 2012, Journal of neuroendocrinology.

Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.

G. Guillon, S. Stoev, M. Manning, 2007, Endocrinology.

Design and synthesis of potent, highly selective vasopressin hypotensive agonists

S. Stoev, M. Manning, H. Szeto, 2006, Journal of peptide science : an official publication of the European Peptide Society.

Discovery and design of novel vasopressin hypotensive peptide agonists.

S. Stoev, M. Manning, W. Y. Chan, 1999, Journal of receptor and signal transduction research.

An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

S. Stoev, M. Manning, W. Kliś, 1995, Journal of peptide science : an official publication of the European Peptide Society.

Potent V2 vasopressin antagonists with structural changes at their C-terminals

S. Stoev, M. Manning, A. Misicka, 1988, Peptides.

Receptor-specific antagonists of vasopressin and oxytocin. A current perspective.

S. Stoev, M. Manning, W. Sawyer, 1993, Annals of the New York Academy of Sciences.

Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

S. Stoev, M. Manning, B. Mouillac, 2005, Journal of peptide science : an official publication of the European Peptide Society.

The Role of the Merrifield Solid Phase Method in the Discovery and Exploration of a New Class of Selective Vasopressin Hypotensive Agonists

S. Stoev, M. Manning, H. Szeto, 2007, International Journal of Peptide Research and Therapeutics.

Design of More Potent, Radioiodinatable and Fluorescent Vasopressin Hypotensive Peptide Agonists

S. Stoev, M. Manning, W. Y. Chan, 2001 .

Position 4 analogues of [deamino‐Cys1] arginine vasopressin exhibit striking species differences for human and rat V2/V1b receptor selectivity

G. Guillon, S. Stoev, M. Manning, 2006, Journal of peptide science : an official publication of the European Peptide Society.

An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally‐restricted, polar and charged amino acids

S. Stoev, M. Manning, A. Olma, 1999, Journal of peptide science : an official publication of the European Peptide Society.

An investigation of position 3 in arginine vasopressin (AVP)

S. Stoev, M. Manning, A. Olma, 2002 .

An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acidsSymbols and abbreviations are in accordance with the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (Eur. J. Biochem. 180, A9-A11, 1989)

S. Stoev, M. Manning, A. Olma, 1999 .

Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure.

S. Stoev, M. Manning, T. Bellini, 2016, Journal of medicinal chemistry.

Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.

S. Stoev, M. Manning, W. Y. Chan, 2009, International journal of peptide and protein research.

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

S. Stoev, M. Manning, B. Mouillac, 2002, Journal of medicinal chemistry.

Synthesis of A7,B7-dicarbainsulin, an analogue with a noncleavable bond between A- and B-chain. II. Synthesis of the A-chain segments.

S. Stoev, G. Videnov, D. Brandenburg, 1989, Biological chemistry Hoppe-Seyler.

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

C. S. Gal, G. Guillon, S. Stoev, 2004, Journal of neuroendocrinology.

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

S. Stoev, M. Manning, A. Misicka, 1990, Journal of medicinal chemistry.

Synthesis and structure–activity investigation of novel vasopressin hypotensive peptide agonists

S. Stoev, M. Manning, W. Y. Chan, 1999, Journal of peptide science : an official publication of the European Peptide Society.

Position Three in Vasopressin Antagonist Tolerates Conformationally Restricted and Aromatic Amino Acid Substitutions: A Striking Contrast with Vasopressin Agonists

S. Stoev, M. Manning, A. Olma, 1997, Journal of peptide science : an official publication of the European Peptide Society.

Highly potent and selective Tyr-NH2 9-containing linear V1 antagonists and D-Tyr2-containing linear V2 agonists: Potential radioiodinated ligands for vasopressin receptors

S. Stoev, M. Manning, W. Sawyer, 1991 .

Discovery of Novel Selective Hypotensive Vasopressin Peptides

S. Stoev, M. Manning, W. Y. Chan, 1998 .

Studies on the total synthesis of an A7,B7-dicarbainsulin. III. Assembly of segments and generation of biological activity.

S. Stoev, G. Videnov, M. Casaretto, 1990, Biological chemistry Hoppe-Seyler.